Astrazeneca Plc Adr Stock Today
| AZN Stock | USD 67.62 0.42 0.63% |
Performance0 of 100
| Odds Of DistressLess than 10
|
AstraZeneca PLC is selling at 67.62 as of the 30th of November 2024; that is 0.63% increase since the beginning of the trading day. The stock's open price was 67.2. AstraZeneca PLC has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Note, on December 14, 2021, Representative Alan S Lowenthal of US Congress acquired under $15k worth of AstraZeneca PLC ADR's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of May 1993 | Category Healthcare | Classification Health Care |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 3.1 B outstanding shares of which 8.07 M shares are presently shorted by investors with about 1.23 days to cover. More on AstraZeneca PLC ADR
Moving together with AstraZeneca Stock
| 0.78 | HLN | Haleon plc | PairCorr |
| 0.9 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.81 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.81 | ANRO | Alto Neuroscience, | PairCorr |
| 0.76 | SHG | Shinhan Financial | PairCorr |
Moving against AstraZeneca Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
AstraZeneca Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Pascal Soriot | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Compulsion (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Nasdaq 100, NASDAQ Biotechnology, NASDAQ Composite, OMX Stockholm, OMX Nordic 40, ARCA Pharmaceutical, OMX Stockholm Large, NASDAQ 100 Pre, OMXS 30 Index, NASDAQ Health Care, OMXS BENCH GI, OMX Stockholm GI, OMX Stockholm 30, Compulsion, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAstraZeneca PLC can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AstraZeneca PLC's financial leverage. It provides some insight into what part of AstraZeneca PLC's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AstraZeneca PLC ADR (AZN) is traded on NASDAQ Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA and employs 89,900 people. AstraZeneca PLC is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 209.66 B. AstraZeneca PLC ADR runs under Pharmaceuticals sector within Health Care industry. The entity has 3.1 B outstanding shares of which 8.07 M shares are presently shorted by investors with about 1.23 days to cover.
AstraZeneca PLC ADR has about 4.52 B in cash with 10.35 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.46.
Check AstraZeneca PLC Probability Of Bankruptcy
Ownership AllocationAstraZeneca PLC holds a total of 3.1 Billion outstanding shares. Almost 83.25 percent of AstraZeneca PLC outstanding shares are held by general public with 16.75 % by other corporate entities. Please note that on December 14, 2021, Representative Alan S Lowenthal of US Congress acquired under $15k worth of AstraZeneca PLC ADR's common stock.
Check AstraZeneca Ownership Details
AstraZeneca Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Fisher Asset Management, Llc | 2024-09-30 | 10.5 M | |
| Atlantic Trust Group, Llc | 2024-06-30 | 9.2 M | |
| Blackrock Inc | 2024-06-30 | 7 M | |
| Capital World Investors | 2024-09-30 | 6.3 M | |
| Gqg Partners Llc | 2024-09-30 | 5.5 M | |
| Neuberger Berman Group Llc | 2024-06-30 | 5.4 M | |
| Ing Investment Management Llc | 2024-06-30 | 5.3 M | |
| Ameriprise Financial Inc | 2024-06-30 | 4.9 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 4.7 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 64.9 M | |
| Primecap Management Company | 2024-09-30 | 42 M |
AstraZeneca PLC Historical Income Statement
AstraZeneca Stock Against Markets
AstraZeneca PLC Corporate Directors
| Marc Dunoyer | Chief Financial Officer, Executive Director | Profile | |
| Sherilyn McCoy | Non-Executive Independent Director | Profile | |
| Genevieve Berger | Non-Executive Independent Director | Profile | |
| Nazneen Rahman | Non-Executive Independent Director | Profile |
Already Invested in AstraZeneca PLC ADR?
The danger of trading AstraZeneca PLC ADR is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AstraZeneca PLC is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AstraZeneca PLC. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AstraZeneca PLC ADR is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.034 | Dividend Share 2.97 | Earnings Share 2.08 | Revenue Per Share 2.7424 | Quarterly Revenue Growth 0.18 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.